Company / Return on Equity (ROE)
United Therapeutics Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
18.8%
FY2025
5-year range
12.0% / 18.8%
FY2021-FY2025
Trend
+1.4%
vs FY2024
Sector context
#23 of 190
Health Care
What the data says
United Therapeutics's return on equity (roe) of 18.8% is higher than 88% of companies in the Health Care sector (FY2025). Return on Equity (ROE) has increased for 5 consecutive years, from -3.8% in FY2019 to 18.8% in FY2025.
Based on SEC 10-K filings.
18.8% in FY2025 with a 3-year CAGR of +3.6%. Top quartile in the Health Care sector.
Improved from 16.5% to 18.8% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +3.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
+137.4% above sector average
Key checks
Key Insights
- United Therapeutics's return on equity (roe) has grown for 4 consecutive years.
- In FY2025, return on equity (roe) increased 1.4% year-over-year.
- Currently 69.1pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 18.8% | +1.4% |
| FY2024 | 18.6% | +12.7% |
| FY2023 | 16.5% | +8.6% |
| FY2022 | 15.2% | +26.1% |
| FY2021 | 12.0% | - |
| FY2020 | - | - |
| FY2019 | -3.8% | -117.8% |
| FY2018 | 21.1% | -48.5% |
| FY2017 | 41.0% | +6.4% |
| FY2016 | 38.6% | -6.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026